Etiological analysis of pale optic disc and its association with six-month visual outcome in patients attending a tertiary care hospital: a prospective observational cohort study.
DOI:
https://doi.org/10.51168/sjhrafrica.v7i2.2754Keywords:
best-corrected visual acuity, optic atrophy, optic neuritis, pale optic disc, prospective cohort, traumatic optic neuropathy, visual outcomeAbstract
Background
Pale optic disc indicates established optic nerve damage caused by inflammatory, ischemic, traumatic, compressive, infectious, toxic, or metabolic disorders. Etiological identification is important because visual recovery varies substantially across causes.
Objectives
To determine the etiological spectrum of pale optic disc and assess its association with six-month best-corrected visual acuity outcome.
Methods
This prospective, hospital-based observational cohort study included 50 adults with optic disc pallor attending a tertiary-care ophthalmology department. Participants underwent standardized ocular examination, colour vision and visual field assessment, selected electrophysiology, laboratory investigations, and neuroimaging when indicated. Visual improvement was defined as a gain of at least one Snellen line at six months. Etiology and visual outcome were compared using Pearson's chi-square test and the Fisher-Freeman-Halton exact test.
Results
The mean age was 38.68 ± 12.09 years, and 56.0% were male. Traumatic optic neuropathy was the leading etiology (28.0%), followed by optic neuritis and tumor-related optic neuropathy (22.0% each) and primary optic atrophy (16.0%). Overall, 17 of 50 patients improved (34.0%; 95% CI, 22.4%-47.8%). Improvement occurred in 72.7% of optic neuritis cases (95% CI, 43.4%-90.3%), 54.5% of tumor-related cases (95% CI, 28.0%-78.7%), and 21.4% of traumatic optic neuropathy cases (95% CI, 7.6%-47.6%). Visual improvement differed significantly by etiology (Pearson χ²(9)=17.62, p=0.040; Fisher-Freeman-Halton exact p=0.011; Cramér's V=0.59).
Conclusion
Pale optic disc had heterogeneous causes and generally guarded visual outcomes. Optic neuritis showed the most favourable recovery, whereas established primary optic atrophy showed no improvement.
Recommendations
Early neuro-ophthalmic assessment, directed imaging, cause-specific treatment, and structured follow-up should be prioritized.
References
Ahmad SS, Blair K, Kanukollu VM. Optic Atrophy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 32644556.
Behbehani R. Clinical approach to optic neuropathies. Clin Ophthalmol. 2007;1(3):233-246. PMID: 19668477; PMCID: PMC2701125.
Biousse V, Newman NJ. Diagnosis and clinical features of common optic neuropathies. Lancet Neurol. 2016;15(13):1355-1367. doi: 10.1016/S1474-4422(16)30237-X. PMID: 27839652. https://doi.org/10.1016/S1474-4422(16)30237-X
Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992;326(9):581-588. PMID: 1734247. https://doi.org/10.1056/NEJM199202273260901
Beck RW, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol. 1993;111(6):773-775. doi: 10.1001/archopht.1993.01090060061023. PMID: 8512477. https://doi.org/10.1001/archopht.1993.01090060061023
Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev. 2015;(8):CD001430. doi: 10.1002/14651858.CD001430.pub4. PMID: 26273799. https://doi.org/10.1002/14651858.CD001430.pub4
Levin LA, Beck RW, Joseph MP, Seiff S, Kraker R. The treatment of traumatic optic neuropathy: the International Optic Nerve Trauma Study. Ophthalmology. 1999;106(7):1268-1277. doi: 10.1016/S0161-6420(99)00707-1. PMID: 10406604. https://doi.org/10.1016/S0161-6420(99)00707-1
Cook MW, Levin LA, Joseph MP, Pinczower EF. Traumatic optic neuropathy. A meta-analysis. Arch Otolaryngol Head Neck Surg. 1996;122(4):389-392. PMID: 8600923. https://doi.org/10.1001/archotol.1996.01890160031006
Liu A, Craver EC, Bhatti MT, Chen JJ. Population-Based Incidence and Outcomes of Compressive Optic Neuropathy. Am J Ophthalmol. 2022;236:130-135. doi: 10.1016/j.ajo.2021.10.018. PMID: 34695397. https://doi.org/10.1016/j.ajo.2021.10.018
Chuenkongkaew W, Samsen P, Thanasombatsakul N. Ethambutol and optic neuropathy. J Med Assoc Thai. 2003;86(7):622-625. PMID: 12948256.
Grzybowski A, Zulsdorff M, Wilhelm H, Tonagel F. Toxic optic neuropathies: an updated review. Acta Ophthalmol. 2015;93(5):402-410. doi: 10.1111/aos.12515. PMID: 25159832. https://doi.org/10.1111/aos.12515
Jung JJ, Baek SH, Kim US. Analysis of the causes of optic disc swelling. Korean J Ophthalmol. 2011;25(1):33-36. doi: 10.3341/kjo.2011.25.1.33. PMID: 21350692; PMCID: PMC3039192. https://doi.org/10.3341/kjo.2011.25.1.33
Kerr NM, Chew SSL, Danesh-Meyer HV. Non-arteritic anterior ischaemic optic neuropathy: a review and update. J Clin Neurosci. 2009;16(8):994-1000. doi: 10.1016/j.jocn.2009.04.002. PMID: 19596112. https://doi.org/10.1016/j.jocn.2009.04.002
Biousse V, Newman NJ. Ischemic Optic Neuropathies. N Engl J Med. 2015;372(25):2428-2436. doi: 10.1056/NEJMra1413352. PMID: 26083207. https://doi.org/10.1056/NEJMra1413352
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Dr. Yeshamalla Bhavana, Dr. Boddupally Soujanya, Dr. Beatrice Choppara

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
















